{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:42:01Z","timestamp":1787877721402,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-024-05615-0","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T01:01:50Z","timestamp":1706144510000},"page":"2365-2372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-young","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"1","key":"5615_CR1","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.26010","volume":"96","author":"R Cornell","year":"2021","unstructured":"Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK et al (2021) Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol 96(1):E5\u2013e8. https:\/\/doi.org\/10.1002\/ajh.26010","journal-title":"Am J Hematol"},{"issue":"5","key":"5615_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, van de Donk N, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36(5):1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"issue":"1","key":"5615_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F et al (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28(1):155\u2013165. https:\/\/doi.org\/10.1038\/leu.2013.115","journal-title":"Leukemia"},{"issue":"8","key":"5615_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381(8):727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"N Engl J Med"},{"issue":"12","key":"5615_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"5615_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"9","key":"5615_CR7","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00277-015-2426-8","volume":"94","author":"G Ihorst","year":"2015","unstructured":"Ihorst G, Waldschmidt J, Schumacher M, W\u00e4sch R, Engelhardt M (2015) Analysis of survival by tumor response: have we learnt any better? Ann Hematol 94(9):1615\u20131616. https:\/\/doi.org\/10.1007\/s00277-015-2426-8","journal-title":"Ann Hematol"},{"issue":"7","key":"5615_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia 36(7):1887\u20131897. https:\/\/doi.org\/10.1038\/s41375-022-01597-y","journal-title":"Leukemia"},{"issue":"3","key":"5615_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV (2021) Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J 11(3):45. https:\/\/doi.org\/10.1038\/s41408-021-00440-4","journal-title":"Blood Cancer J"},{"issue":"6","key":"5615_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart\u00ednez-L\u00f3pez J, Sidana S, Delforge M et al (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"issue":"24","key":"5615_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"issue":"10297","key":"5615_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O\u2019Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"8","key":"5615_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"1","key":"5615_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/jha2.120","volume":"2","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Richter J, Biran N, Siegel D, Reichmann W, Li L, Tang S, Saint-Martin JR, Joshi A, Kauffman M, Shah J, Shacham S, Lonial S (2021) Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem 2(1):48\u201355. https:\/\/doi.org\/10.1002\/jha2.120","journal-title":"EJHaem"},{"issue":"1","key":"5615_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","volume":"20","author":"L Qiu","year":"2022","unstructured":"Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, An G, Wei Y, Cai Z, Gao S, Weng J, Chen L, Jing H, Li F, Liu Z, Chen X, Liu J, Wang A, Yu Y et al (2022) Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med 20(1):108. https:\/\/doi.org\/10.1186\/s12916-022-02305-4","journal-title":"BMC Med"},{"key":"5615_CR16","doi-asserted-by":"publisher","first-page":"7152","DOI":"10.1182\/blood-2022-165924","volume":"140","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Malandrakis P, Spiliopoulou V, Ntanasis-Stathopoulos I, Solia E, Theodorakakou F, Syrigou R, Kokkali N-A, Migkou M, Papaiakovou EE, Fotiou D, Roussou M, Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA (2022) Real world efficacy and toxicity of selinexor: importance of dose intensity and post progression outcomes. Blood 140:7152\u20137153","journal-title":"Blood"},{"key":"5615_CR17","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2021-146003","volume":"138","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Facon T, Badros AZ, Levy M, Moreau P, Delimpasi S, Simonova M, Spicka I, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK et al (2021) Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the Boston study. Blood 138:3793\u20133793. https:\/\/doi.org\/10.1182\/blood-2021-146003","journal-title":"Blood"},{"issue":"7","key":"5615_CR18","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","volume":"22","author":"AK Nooka","year":"2022","unstructured":"Nooka AK, Costa LJ, Gasparetto CJ, Richardson PG, Siegel DS, Chari A, Lentzsch S, Jagannath S, Mikhael J (2022) Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from International Myeloma Foundation expert roundtable. Clin Lymphoma Myeloma Leuk 22(7):e526\u2013e531. https:\/\/doi.org\/10.1016\/j.clml.2022.01.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"5615_CR19","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1016\/j.clml.2021.07.014","volume":"21","author":"A Chari","year":"2021","unstructured":"Chari A, Florendo E, Mancia IS, Cho H, Madduri D, Parekh S, Richter J, Dhadwal A, Thomas J, Jiang G, Lagana A, Bhalla S, Jagannath S (2021) Optimal supportive care with selinexor improves outcomes in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 21(12):e975\u2013e984. https:\/\/doi.org\/10.1016\/j.clml.2021.07.014","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05615-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05615-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:03:27Z","timestamp":1720109007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05615-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5615"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05615-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki or comparable ethical standards. Waiving any informed consent was approved by the institutional review boards of the respective sites (Chung-Ang University Hospital, 2202-021-19407; Seoul St. Mary\u2019s Hospital, KIRB-20220614-031; National Cancer Center, 2022-0039; Seoul National University hospital, H-2202-079-1301; Gachon University, GDIRB2022-054; Chonnam National University, 2023-041; Samsung Medical Center, SMC 2022-03-076-001). The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}